**Core tip:** Delayed gastric emptying (DGE) after distal gastrectomy is a significant postoperative complication, and appropriate treatment measures are not yet available. This retrospective study investigated the efficacy and safety of self-expandable metallic stents in patients with DGE after gastric surgery. We found that endoscopic stent placement provided prompt relief of obstructive symptoms, with a low rate of complications, and no need for additional surgical interventions.

INTRODUCTION
============

Gastric cancer is one of the most common types of gastrointestinal malignancies. Every year, 950000 people are newly diagnosed with gastric cancer and 700000 gastric cancer-related deaths occur\[[@B1]-[@B4]\]. Although endoscopic therapy is a useful and effective therapeutic modality for early gastric cancer, to date the only curative treatment option has been surgical resection. Recently, laparoscopy-assisted gastrectomy, which is less invasive than conventional gastrectomy, with or without lymph node dissection, has become the mainstay of surgical management. With minimally invasive surgery becoming popular, the quality of life after surgical resection has improved\[[@B5]-[@B9]\]. Despite the use of advanced techniques, complications related to surgery are unavoidable. After gastric resection, bowel recovery can be delayed in a proportion of patients. Postgastrectomy syndromes, such as reflux esophagitis and dumping syndrome, can occur after distal gastrectomy. These complications are closely associated with the frequency of gastric emptying\[[@B10],[@B11]\]. Moreover, longstanding gastric stasis following gastric resection can occur occasionally. The prevalence of postoperative delayed gastric emptying (DGE) has been shown to be between 5% and 30%\[[@B12]-[@B14]\]. It is characterized by an inability to consume regular meals with no evidence of anatomical narrowing or obstruction. Functional abnormality or inflammation at the anastomotic site could also lead to postoperative DGE. Sometimes, DGE may be associated with major postoperative adverse events, such as pancreatitis or pneumonia, and truncal vagotomy\[[@B12]\]. Moreover, it is likely that there are other unknown causes that cannot be clinically explained.

The primary therapeutic approach for postoperative DGE could be observation with nutritional support and administration of prokinetics. Reoperation to treat postoperative DGE is performed only in patients exhibiting severe and longstanding symptoms of outlet obstruction, necessitating drainage or non-oral route feeding\[[@B14],[@B15]\]. However, there have been no suitable recommendations for the treatment of postoperative DGE.

Recently, self-expandable metallic stent (SEMS) placement has emerged as an effective and practical method not only for the management of gastrointestinal malignancy-associated narrowing or obstruction but also for benign stenosis or leaks of the gastrointestinal tract\[[@B16]-[@B18]\]. To the best of our knowledge, there has been no study mentioning the efficacy and safety of SEMS in patients with DGE after gastrectomy. We assumed that SEMS placement in the outlet area may facilitate rapid resumption of oral intake of foods and recovery of general patient conditions, resulting in a shorter hospital stay in patients with DGE after gastrectomy. We analyzed and described our experience with SEMS placement in patients with DGE exhibiting longstanding obstructive symptoms after gastrectomy.

MATERIALS AND METHODS
=====================

Patient enrolment
-----------------

We prospectively collected data from June 2010 to April 2017. The total number of distal gastrectomies performed during the same period was 891. Twenty patients (2.2%) underwent stent insertion for postoperative DGE. DGE was defined as the failure to consume and/or tolerate a regular diet even after the seventh postoperative day\[[@B14],[@B19],[@B20]\]. We enrolled postoperative DGE patients who were not responsive to conservative management. Patients were kept "nil per oral" (NPO) and received conservative management with nutritional support and administration of prokinetics before stent placement.

For each case, we recorded the diagnosis, type of gastric procedure performed, hospital course, postoperative day when oral food intake was resumed, and postoperative problems. All patients were assessed using gastroscopy and upper gastrointestinal (UGI) series with gastrografin during diagnosis and treatment (Figure [1](#F1){ref-type="fig"}).

![Delayed gastric emptying fourteen days after subtotal gastrectomy. A: Food is retained in the remnant stomach because of passage delay at the anastomotic site; B: An endoscope is passed through the anastomotic site; C: On gastroscopy, a patent lumen with edematous mucosa is observed on the efferent loop side; D: Despite the patency of the E-loop, delayed gastrojejunal passage is seen on upper gastrointestinal series.](WJG-24-4578-g001){#F1}

Patients who were suspected of DGE, but did not undergo gastroscopy or UGI series testing, were excluded from the study. This study was reviewed by and ethical approval was obtained from the Korea University Anam Hospital Institutional Review Board (IRB No. ED13047).

Surgical procedure
------------------

Procedures were performed according to standard treatment algorithms\[[@B21]\]. Laparoscopy-assisted distal gastrectomy (LADG) was performed by two surgeons with considerable experience with the procedure. During surgery, resection was performed, leaving an adequate resection margin. D2 lymph node dissection was performed according to guidelines in all patients. Reconstruction after gastrectomy was performed using one of the following reconstruction methods depending on the surgeon's preference: (1) Billroth I gastroduodenostomy and (2) Billroth II gastrojejunostomy. During surgery, the vagal nerve was preserved because it has been shown to be helpful in improving the quality of life after gastrectomy by decreasing the occurrence of diarrhea and formation of postgastrectomy gallstones\[[@B22]\]. All surgical procedures were performed under general anesthesia. Postoperative oral food intake was permitted following the first bowel movement.

Stent characteristics
---------------------

The stent (M. I. Tech, Seoul, South Korea) diameters ranged from 18-20 mm and were 70-, 90-, and 110-mm long. All SEMSs used were partially covered; their central body portion was covered with a silicone membrane and the flared portions of both ends were bare. The length of the stent was determined by the endoscopist based on the appearance of gastrojejunostomy anastomotic site and the efferent loop.

Stent placement
---------------

Endoscopic stent deployment was performed using a GIF-2TQ260M endoscope (Olympus Optical Co., Ltd, Tokyo, Japan). An experienced endoscopist performed stent placement following a combined fluoroscopic and endoscopic method (Figure [2](#F2){ref-type="fig"}). Stent placement was performed according to the procedural details described previously\[[@B23]\]. All procedures were performed under standard conscious sedation using propofol and/or midazolam. Patients were maintained in either the left decubitus or prone position during stent placement.

![Placement of self-expandable metal stent. A: A catheter is placed through the lumen; B: A self-expandable metal stent (10-mm in length) is released following adjustment for the suitable position.](WJG-24-4578-g002){#F2}

Definitions
-----------

We defined technical success of stent placement as the adequate deployment of the stent at the anastomosis site. Satisfactory relief of gastric stasis at 14 d was defined as clinical success, after which resumption of oral intake was possible. Early symptom improvement was defined as oral intake resumption within 2 d following stent placement.

Patient follow-up
-----------------

Patients were followed up until they were lost to follow-up or dead. During follow-up, symptom improvement was evaluated by gastroscopy, interviews with patients, and abdominal radiographic examination. Patient symptoms and obstructive signs were monitored and used to identify stent failure. When stent failure was suspected, endoscopic assessment and abdominal radiography were performed to evaluate patency. Data were acquired from endoscopic findings, radiologic reports, and clinical records.

Statistical analysis
--------------------

Data are shown as mean, median, standard deviation, and percentages. The stent maintenance period determined during follow-up was assessed by Kaplan-Meier analysis. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY, United States).

RESULTS
=======

Patient population
------------------

The mean patient age was 65.9 ± 11.4 years (range 35-82 years) (Table [1](#T1){ref-type="table"}). Gastroscopic examination presented no mechanical obstruction or stricture of the anastomotic site in any patient, and the gastroscope could freely pass through the gastroenteric anastomosis. The UGI series showed contrast passage delay through the anastomosis, but no obvious mechanical obstruction, stricture, or leakage of anastomosis was observed. Baseline gastric outlet obstruction scoring system (GOOSS) scores suggested that patients had adjusted their diet to compensate for DGE (Table [2](#T2){ref-type="table"}).

###### 

Baseline characteristics *n* (%)

  **Variable**                **Number of patients**
  --------------------------- ------------------------
  Sex                         
  Male                        13 (65)
  Female                      7 (35)
  Comorbidity                 
  DM                          6 (30)
  HTN                         7 (35)
  Psychological disorder      3 (15)
  Histologic type             
  Well differentiated         3 (15)
  Moderately differentiated   5 (25)
  Poorly differentiated       12 (60)
  Tumor location              
  Body                        9 (45)
  Antrum                      11 (55)
  Operation method            
  LADG, B-I                   10 (50)
  LADG, B-II                  10 (50)

DM: Diabetes mellitus; HTN: Hypertension; LADG: Laparoscopy-assisted distal gastrectomy; B-I: Billroth-I; B-II: Billroth-II.

###### 

Baseline gastric outlet obstruction scoring system score and obstructive symptoms *n* (%)

  **Characteristic**               **Number of patients**
  -------------------------------- ------------------------
  GOOSS score                      
  No oral intake (0)               5 (25)
  Only liquid diet (1)             10 (50)
  Soft solid diet (2)              5 (25)
  Low residue or normal diet (3)   0 (0)
  Obstructive symptom              
  Abdominal pain                   
  None                             7 (35)
  Moderate                         12 (60)
  Severe                           1 (5)
  Vomiting                         
  None                             5 (25)
  Moderate                         10 (50)
  Severe                           5 (25)
  Nausea                           
  None                             3 (15)
  Moderate                         11 (55)
  Severe                           6 (30)
  Regurgitation                    
  None                             5 (25)
  Moderate                         10 (50)
  Severe                           5 (25)

GOOSS: Gastric outlet obstruction scoring system.

Procedural details
------------------

A total of 20 patients underwent stent placement for DGE after distal gastrectomy (Figure [3](#F3){ref-type="fig"}). Technical success was achieved in all patients (100%). Procedures were performed using forward-viewing gastroscopes in all patients. The most frequently deployed stent length was 90 mm (65%), followed by 70 mm (25%) and 110 mm (10%) (Table [3](#T3){ref-type="table"}). After stent placement, patients remained hospitalized for a mean of 6.8 ± 4.6 d (range 2-21 d).

###### 

Comparison of details between patients

  **Patient No**.   **Tumor location**   **Operation type**   **Stent type**         **Duration for Symptom improvement**   **Stent patency**   **Duration from operation to stent placement**   **Hospital stay after stent insertion**   **Total hospital stay**
  ----------------- -------------------- -------------------- ---------------------- -------------------------------------- ------------------- ------------------------------------------------ ----------------------------------------- -------------------------
  1                 Antrum               LADG (B-I)           90-mm covered stent    2                                      758                 17                                               7                                         31
  2                 Antrum               LADG (B-I)           90-mm covered-stent    3                                      80                  25                                               5                                         34
  3                 Mid body             LADG (B-I)           70-mm covered stent    1                                      2114                28                                               7                                         38
  4                 Low body             LADG (B-II)          90-mm covered stent    2                                      54                  27                                               6                                         35
  5                 Low body             LADG (B-I)           90-mm covered stent    2                                      17                  31                                               3                                         36
  6                 Body                 LADG (B-II)          70-mm covered stent    6                                      6                   26                                               10                                        37
  7                 Antrum               LADG (B-II)          110-mm covered stent   5                                      194                 23                                               13                                        42
  8                 Body                 LADG (B-I)           90-mm covered stent    3                                      9                   28                                               12                                        42
  9                 Antrum               LADG (B-II)          70-mm covered stent    2                                      14                  14                                               4                                         25
  10                Antrum               LADG (B-II)          90-mm covered stent    1                                      98                  12                                               5                                         21
  11                Antrum               LADG (B-I)           90-mm covered stent    5                                      8                   24                                               8                                         35
  12                Low body             LADG (B-I)           70-mm covered stent    1                                      1675                7                                                2                                         21
  13                Body                 LADG (B-II)          110-mm covered stent   2                                      24                  14                                               6                                         23
  14                Antrum               LADG (B-II)          90-mm covered stent    2                                      40                  9                                                8                                         25
  15                Antrum               LADG (B-I)           90-mm covered stent    1                                      51                  15                                               3                                         20
  16                Antrum               LADG (B-II)          90-mm covered stent    1                                      42                  23                                               2                                         27
  17                Body                 LADG (B-II)          90-mm covered stent    1                                      64                  11                                               21                                        35
  18                Body                 LADG (B-I)           90-mm covered stent    1                                      23                  21                                               3                                         31
  19                Antrum               LADG (B-II)          90-mm covered stent    1                                      4                   9                                                9                                         19
  20                Antrum               LADG (B-II)          70-mm covered stent    0                                      52                  9                                                2                                         21

LADG: Laparoscopy-assisted distal gastrectomy; B-I: Billroth-I; B-II: Billroth-II.

![Inserted self-expandable metal stent. A: A stent is deployed at the anastomotic site with endoscopic clips; B: The stent is identified on an abdominal radiograph (arrow).](WJG-24-4578-g003){#F3}

Stent patency
-------------

Stent patency at 14 d was 80% (16 patients). Before the 14^th^ d follow-up, four patients experienced stent migration, but they had no significant symptoms and did not need further intervention. Mean follow-up period was 1178.3 ± 844.1 d (Figure [4](#F4){ref-type="fig"}). Stent maintenance period determined during follow-up was assessed by Kaplan-Meier analysis (Figure [5](#F5){ref-type="fig"}). The median stent maintenance duration was 51 d (range 6-2114 d). In a patient with preserved stent maintenance, 1-year follow-up gastroscopy revealed a slightly stenotic anastomotic site with a metal stent, but the gastroscope could be passed. Granulation tissue was observed around the anastomotic site.

![Patent anastomotic site on follow-up gastroscopy. A: Anastomotic lumen is patent; B: The stent is not identified on a follow-up abdominal radiograph.](WJG-24-4578-g004){#F4}

![Kaplan--Meier estimates of the stent maintenance period. The Kaplan--Meier curve is shown. At 30 d, the estimated stent maintenance rate is 58.8%. Inserted stents were passed per rectum spontaneously in 14 of 20 patients (70%) with no significant complications.](WJG-24-4578-g005){#F5}

Clinical outcomes
-----------------

During the study, over 90% of patients experienced relief in the obstructive symptoms after stent placement compared with the baseline obstructive symptoms (Table [4](#T4){ref-type="table"}). After stent placement, early symptom improvement was achieved in 15 of 20 patients (75%). The rate of clinical success 14 d after stent placement was 100%. During the follow-up period, inserted stents were spontaneously passed per rectum in 14 of 20 patients (70%) and no significant complications were noted. Moreover, symptom improvement was maintained after stent placement without the requirement of any additional stent or surgical procedure in 19 of 20 patients (95%).

###### 

Change in severity of obstructive symptoms (abdominal pain, vomiting, nausea, and regurgitation) after stent placement

  **Characteristics**                                                            **1 yr**   **2 yr**   **3 yr**   **4 yr**   **5 yr**
  ------------------------------------------------------------------------------ ---------- ---------- ---------- ---------- ----------
  Number of patients available for follow-up                                     15         10         8          7          3
  Patients with all symptoms maintained or improved compared with baseline (%)   93         90         100        100        100
  Patients with any symptom worsening compared to baseline (%)                   7          10         0          0          0

Adverse events
--------------

There was no procedure- or device-associated mortality in this study. After stent placement, there were no immediate adverse events, such as perforation or aspiration pneumonia (Table [5](#T5){ref-type="table"}). The most common GI adverse event was stent migration. Stent migration occurred between 6 and 194 d after stent placement. Most of the migrated stents spontaneously passed per rectum. In one patient, the stent had migrated into the stomach, and stent extraction was performed with rat tooth forceps. In another patient, a stent fracture was noted and an additional stent was inserted immediately. Two further patients experienced severe abdominal pain. All these events were considered to be associated with postsurgical bowel adhesion and were not stent related. There was no adverse event caused by distal stent migration.

###### 

Gastrointestinal events after self-expandable metallic stent insertion

  **Adverse event**       **Total number of events**   **% of patients**   **Stent-related events**   **% of patients**
  ----------------------- ---------------------------- ------------------- -------------------------- -------------------
  Stent occlusion         0                            0                   0                          0
  GI bleeding             0                            0                   0                          0
  Bowel perforation       0                            0                   0                          0
  Severe abdominal pain   2                            11.1                0                          0
  Stent migration         15                           83.3                15                         93.7
  Stent fracture          1                            5.6                 1                          6.3
  Total                   18                           100                 16                         100

GI: Gastrointestinal.

DISCUSSION
==========

In the present study, we evaluated the efficacy of SEMS insertion for DGE following surgical gastrectomy. Endoscopic stent placement provides prompt relief of obstructive symptoms.

During the first 1-3 wk after distal gastrectomy, postoperative DGE can occur due to different potential causes\[[@B12]-[@B14]\]. Of these, a mechanical problem may be the cause of the persistent increase in gastric remains. Acute angulation, kinking, long-term edema, or congestion of anastomotic lesions may also cause postoperative DGE. To date, various therapeutic approaches have been used for the treatment of postoperative DGE\[[@B19],[@B20]\]. Although initial observation with conservative management including non-oral-route nutritional support is preferred, it is difficult for patients to maintain NPO status for more than 2-3 wk. Moreover, there is no appropriate way to evaluate the degree of improvement of DGE; thus, decision-making regarding treatment continuation or termination is difficult. Reoperation might be performed in situations in which nutritional support by a feeding jejunostomy is needed or when an efferent limb or stomal obstruction occurs\[[@B12]\]. However, reoperation increases the risk of morbidity and mortality, although it might appear to be more effective than conservative treatment. The current methods for postoperative DGE might therefore present less effective outcomes or potential morbidity associated with medications or surgical procedures.

If DGE in a patient improves after a short duration of conservative management, further therapeutic planning is not needed. If not, the subsequent therapeutic step needs to be planned. It is often preferable not to select surgery directly, but to plan a bridge or substitutive therapy that can likely fill the gap. In such a clinical situation, stent placement could be ideal, compared with medical conservative treatment or reoperation.

In this study, stent placement rapidly resolved obstructive symptoms without severe adverse events and the patient could be discharged with resumption of oral intake within a short duration after stent insertion. The stenting procedure itself is a minimally invasive therapeutic approach, which can be performed using simple fluoroscopy-guided endoscopy. Although experts are required for stent insertion, it is a relatively simple procedure. After stent insertion, patients did not require prolonged fasting or hospitalization, while the quality of life of patients improved, and adverse events did not occur. We did not need to remove the inserted stent in any patient. Deployed stents were passed per rectum spontaneously after some time. There were no associated complications.

At present, literature concerning stent placement for DGE after surgical gastrectomy is scarce. Stent deployment in patients with DGE after distal gastrectomy in this study resulted in effective and favorable outcomes. It is difficult to determine an optimal time for stent removal as early removal may decrease the effect of stenting and late removal could induce stent ingrowth. Therefore, we did not make a fixed decision regarding the appropriate timing of stent extraction. We did not extract the deployed stent because we believed that it would be better if it remained in position for as long as possible. We performed endoscopic clipping at the proximal end of the stent to prevent immediate migration after stent placement as there was no anatomical stenosis that would induce mechanical obstruction. When the stent migrated, it was passed per rectum spontaneously without any adverse events and did not need any surgical procedure.

Considering these results, physicians should consider stent placement in patients with postoperative DGE, especially, when rapid oral diet resumption could be helpful for patients. This method can relieve obstructive symptoms rapidly, shorten hospital stay, and increase patient satisfaction, and quality of life.

In conclusion, endoscopic stent placement resulted in a high technical success rate and rapid symptom improvement in patients with postoperative DGE. Further surgical intervention was not necessary in all cases. Endoscopic stenting could be considered a useful treatment option for DGE after gastrectomy.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Delayed gastric emptying (DGE) after gastric surgery is one of the main postoperative complications. However, there have been no appropriate treatment measures for this distressing clinical situation. Recently, self-expandable metallic stent (SEMS) placement has become an effective and practical method not only for the management of gastrointestinal malignancy-associated problems but also for benign stenosis or leaks of the gastrointestinal tract.

Research motivation
-------------------

The currently available methods for postoperative DGE might present less effective outcomes or potential morbidities associated with medications or surgical procedures.

Research objectives
-------------------

The objective of this study was to analysis whether SEMS placement in the outlet area may facilitate rapid resumption of oral food intake and recovery of the general condition, resulting in shorter hospital stays in patients with DGE after gastrectomy.

Research methods
----------------

We prospectively collected data from 20 patients who underwent stent insertion for postoperative DGE. We recorded the diagnosis, type of gastric procedure performed, hospital course, postoperative day when oral food intake was resumed, and postoperative problems. Assessment for clinical improvement, complications, and consequences after stent insertion were performed.

Research results
----------------

Stent placement for postoperative DGE relieved obstructive symptoms rapidly, shortened hospital stay, and increased patient satisfaction and quality of life. Endoscopic stent placement presented a high technical success rate and rapid symptom improvement in patients with postoperative DGE. Moreover, no further surgical procedures were necessary in all cases. Endoscopic stenting could be considered a useful treatment option for DGE after gastrectomy.

Research conclusions
--------------------

This study showed the efficacy of SEMS insertion for DGE following surgical gastrectomy. Endoscopic stent placement provides prompt relief of obstructive symptoms due to various causes after distal gastrectomy. The stenting procedure itself is a minimally invasive therapeutic alternative, which can be performed via simple fluoroscopy-guided endoscopy. After stent insertion, patients did not require prolonged fasting or hospitalization, the quality of life of the patients improved, and adverse events did not occur. Physicians could consider stent placement in patients with postoperative DGE, especially, when rapid oral diet resumption could be helpful for patients.

Research perspectives
---------------------

Endoscopic stent placement, which is minimal invasive procedure, resulted in a high technical success rate and rapid symptom improvement in patients with postoperative DGE. In future research, direct comparison of clinical efficacy between stent placement and other therapeutic method could be helpful for physicians.
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